Levoxyl — Class II drug recall D-0339-2019
Terminated recall by Pfizer Inc., reported 2018-12-26, distributed nationwide. Superpotent Drug.
| Recall number | D-0339-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pfizer Inc., New York, NY, United States |
| Recall initiated | 2018-12-06 |
| Classified | 2018-12-18 |
| Reported by FDA | 2018-12-26 |
| Terminated | 2020-10-08 |
| Distributed | Nationwide (US) |
| Quantity | 1,996 bottles |
| Reason classes | potency |
| NDC | 60793-0850, 60793-0850-01, 60793-0850-10, 60793-0851, 60793-0851-01, 60793-0851-10, 60793-0852, 60793-0852-01, 60793-0852-10, 60793-0853, 60793-0853-01, 60793-0853-10, 60793-0854, 60793-0854-01, 60793-0854-10, 60793-0855, 60793-0855-01, 60793-0855-10, 60793-0856, 60793-0856-01, 60793-0856-10, 60793-0857, 60793-0857-01, 60793-0857-10, 60793-0858 and 8 more |
| Lot numbers | 18A18 |
| Expiration dates | 2020-01 |
Product
Levoxyl (levothyroxine sodium tablets, USP) tablets 112 mcg, 100-count bottle, Rx Only,Distributed by Pfizer Inc. New York, NY 10017, NDC 60793-855-01
Reason for recall
Superpotent Drug.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0339-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.